Evidence map›Paper›PMID 40808683›Full record

SynthesisFrontiers in pharmacology2025

Efficacy and safety of different medications compared for the treatment of postherpetic neuralgia: a network meta-analysis.

Zhen Guo, Yunfan Xia, Zuyong Zhang

Abstract readSystematic Review
In one paragraph

Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Article
  4. Observational
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Zhen GuoThe Fourth Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Yunfan XiaThe Third Clinical Medical College of Zhejiang Chinese Medical University, Hangzhou, Zhejiang, China.
Zuyong ZhangHangzhou Third People's Hospital Affiliated to Zhejiang Chinese Medical University, Hangzhou, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Postherpetic neuralgia (PHN) is a neuropathic pain and the most common complication of herpes zoster (HZ). Pharmacotherapy serves as the primary intervention for alleviating pain associated with PHN. Methods: Electronic databases were systematically searched to identify randomized controlled trials (RCTs) evaluating pharmacotherapy for PHN. The network meta-analysis (NMA) based on the Bayesian framework was analyzed using R4.4.1 and Stata18.0 software. Results: A total of 38 RCTs were included in the analysis, enrolling 8,621 participants. In the Risk of Bias 2.0 (RoB 2.0) tool, nine studies (24%) were assessed as having a high risk of bias, 15 studies (39%) were rated as having some concerns, and 14 studies (37%) were assessed as having a low risk of bias. The NMA results showed that the NGX-4010 8% capsaicin patch had a statistically significant effect in terms of pain intensity (MD = -9.20, 95% CI: [-12.0, -6.60]). The secondary outcomes showed a significant effect of hydromorphone in improving sleep quality (MD = -3.8, 95% CI: [-23.0, -15.0]) and decreasing pain questionnaire scores (MD = -13.0, 95% CI: [-28.0, 2.1]). Amitriptyline plus pregabalin demonstrated the highest probability of clinical superiority (SUCRA = 0.92). The AE incidence results showed that opioids were identified as having the highest cumulative ranking (SUCRA = 0.87). Conclusion: The study showed that capsaicin patches and hydromorphone were more significant in relieving pain in PHN, whereas calcium channel modulators were more comprehensive in clinical management. The inclusion of more high-quality articles was needed to support this evidence due to quality bias in the literature.

Indexed as

drug thearpyherpes zosternetwork meta-analysispostherpetic neuralgiarandomized controlled trial

Identifiers

PMID40808683
PMCPMC12343574

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.